<DOC>
	<DOCNO>NCT00689000</DOCNO>
	<brief_summary>This open-label , non-randomised , multi-centre phase I-II study CHR-2797 administer orally day . The study involve two distinct phase : - Phase I : open-label , dose-escalating phase study explore safety , tolerability , pharmacokinetics ( PK ) CHR-2797 . - Phase II : recommend dose level CHR-2797 , determine phase I , administer cohort approximately 40 patient determine whether CHR-2797 sufficient biological activity disease ( ) study .</brief_summary>
	<brief_title>Safety Anti-Disease Activity CHR-2797 ( Tosedostat ) Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia ( AML ) Multiple Myeloma ( MM )</brief_title>
	<detailed_description>This open-label , non-randomised , multi-centre phase I-II study CHR-2797 administer orally day . The study involve two distinct phase : Phase I : open-label , dose-escalating phase study explore safety , tolerability , pharmacokinetics ( PK ) CHR-2797 . Cohorts 3-6 patient treat escalate , daily , oral dos CHR-2797 84 day ( 12 week ) , first 28 day constitute dose finding/ DLT phase . The start dose 60 mg daily . Doses increase stepwise fashion around 40 percent per step MTD reach . The proportion patient Multiple Myeloma limit one third : one per cohort 3 2 per cohort 6 . It anticipate 24-30 patient enrol phase I portion trial . A decision make regard disease indication test phase II ( either AML/MDS MM ) , completion phase I , follow definition MTD . Phase II : recommend dose determined phase I , administer 84 day maximum 40 patient . The primary objective determine whether CHR-2797 sufficient biological activity disease ( ) study . A multinomial stopping rule include design incorporates objective response early progression decision stop continue phase I/II trial . An interim assessment perform 15 patient receive maximum acceptable dose ( MAD ) dose CHR-2797 clearly define early stopping rule . There clinical conference end every cohort phase I portion study , phase I II first 15 patient complete therapy phase II .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Signed , informed consent . Patients AML , MDS ( subtype RAEB1 RAEB2 ) , MM whose disease relapse refractory front line and/ salvage therapy ; elderly patient ( ≥ 60 year ) AML , MDS , MM candidate chemotherapy therapy inappropriate . Patients recover acute adverse effect prior therapy ( exclude alopecia grade II neuropathy ) . AML , MDS MM diseases haematopoietic system cause myelosuppression . Consequently supportive therapy give ensure adequate value , accord local guideline . A bone marrow aspirate/ biopsy perform within four week prior study entry . Adequate bone marrow , hepatic renal function include follow : 1 . Patients high blast count include trial , control use hydroxyurea ( 5003000 mg daily ) . 2 . Total bilirubin ≤ 1.5 x upper normal limit . 3 . AST ( SGOT ) , ALT ( SGPT ) ≤ 2.5 x upper normal limit . 4 . Creatinine ≤1.5 x upper normal limit . Age ≥ 18 year Performance status ( PS ) ≤ 2 ( ECOG scale ) . Estimated lifeexpectancy great 3 month . Female patient reproductive potential must negative serum pregnancy test within 7 day prior start trial . A woman reproductive potential define one biologically capable become pregnant . Patients surgically sterile postmenopausal must agree use medically acceptable highly effective method birth control duration study continue end CHR2797 treatment 3 month ( female patient ) 6 month ( male patient partner ) . A highly effective method birth control define method result low failure rate , include implant , injectables , intrauterine device ( IUD 's ) , sexual abstinence , vasectomy/ sterilization . Sexually active male female use oral contraceptive pill also use barrier contraception . Although reason believe use CHR2797 effect pharmacokinetics hormonal contraceptive , yet prove . Anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within 4 week prior trial entry except hydroxyurea ( maximum daily dose 3 g ) . Indolent , smoulder myeloma , monoclonal gammopathy unknown significance . Patients need daily dose hydroxyurea great 3 g control leukocytosis . Coexisting active infection serious concurrent illness . Any coexist medical condition investigator 's judgement substantially increase risk associate patient 's participation study Psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary study . Gastrointestinal disorder may interfere absorption study drug . Patients platelet count ( ) &lt; 20,000 . Patients blood transfusion ( platelet support pack cell ) within 7 day prior study entry . Persistent grade II great toxicity cause ( except haematological toxicity peripheral neuropathy ) . Patients grade IIIIV peripheral neuropathy . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>MM</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hematological malignancy</keyword>
	<keyword>Elderly</keyword>
	<keyword>Refractory</keyword>
	<keyword>Blood</keyword>
</DOC>